Moreover, KDM3A activates ER-target genes and promotes ER-positive BC growth and resistance to endocrine therapy, whereas KDM3A and KDM4B interact to co-regulate pro-proliferative and ER-target genes. The gene discussed is KDM3A; the disease is breast cancer.